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ABSTRACT
Introduction Despite the low prevalence of HIV and broad 
provision of antiretroviral therapy, the Middle East and North 
Africa (MENA) remains the only region where new HIV 
infections and AIDS- related deaths are not declining. There 
is a dearth of evidence from MENA on antiretroviral therapy 
engagement. In this qualitative study, we sought to identify the 
ways in which successful treatment is hindered in Iran, which 
is home to 24% of HIV infections in MENA.
Methods From August 2018 to January 2019, we used 
purposive sampling and conducted 12 individual interviews 
and 8 focus group discussions with 27 female and 31 
male patients, in addition to 5 individual interviews with HIV 
care providers and 1 focus group discussion with 8 care 
providers. Social constructivism augmented with realist- 
informed thematic analysis was used to understand how 
the socioecological context triggers cognitive and affective 
mechanisms that disrupt antiretroviral therapy.
Results The use of Thematic Network Analysis resulted 
in the identification of three key cognitive and affective 
mechanisms that appear to shape treatment experience and 
are triggered via HIV’s socioecological context and changing 
economic conditions in Iran: denial in response to societal 
negative perceptions of HIV; fear in response to societal lack 
of awareness regarding HIV and misinformation; and despair 
in response to HIV- related stigma and enacted discrimination, 
economic insecurity and social support.
Conclusions To our knowledge, this is the first study within 
MENA to identify pathways through which successful treatment 
is hindered. It appears that lack of societal awareness regarding 
HIV is specific to low prevalence settings, such as MENA 
countries, where negative perceptions, stigma, discrimination 
and misinformation regarding HIV and its treatment produce 
denial, fear and despair, acting as mechanisms that disrupt 
antiretroviral therapy. The experience of despair, in response 
to changing economic conditions and social support, further 
impacts treatment experience.
INTRODUCTION
The Middle East and North Africa (MENA) 
region is considered to be a ‘black- hole’ 
in terms of HIV/AIDS research.1 Despite 
provision of antiretroviral therapy, new HIV 
infections continue to rise and AIDS- related 
deaths remain stagnantly high in most MENA 
countries, in contrast to the rest of the world.2 
Only 67% of people diagnosed with HIV in 
MENA receive treatment, and of those only 
83% are reported to be virally suppressed, 
indicating that engagement with care and 
adherence to treatment are key contributing 
factors to HIV- related outcomes.
Yet, there is a dearth of evidence from 
MENA countries on the lived experience of 
engaging with lifelong treatment.3–6 Of the 
Key questions
What is already known?
 ► Globally, adherence to antiretroviral therapy is im-
pacted by political, sociostructural, institutional, in-
terpersonal and individual factors.
 ► Within the Middle East and North Africa region, 
a knowledge gap exists in terms of the context of 
engagement with and adherence to antiretroviral 
therapy.
What are the new findings?
 ► Three key cognitive and affective mechanisms of 
denial, fear and despair were found to interfere with 
successful antiretroviral therapy among Iranians liv-
ing with HIV.
 ► Socioecological pathways that trigger denial, fear 
and despair are detailed and considered within the 
changing economic conditions of sanctions and 
inflation.
What do the new findings imply?
 ► Low prevalence of HIV stifles public knowledge 
about HIV and heightens stigma, discrimination and 
negative perceptions that afflict people living with 
HIV.
 ► Reducing or intentionally stopping adherence to an-
tiretroviral therapy appears to be manifested in cli-
mates of economic insecurity that increase despair 
and suicidal thoughts.
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few studies conducted within MENA, most focus on prev-
alence or biomedical aspects of the condition,7–10 and 
studies of adherence focus on identifying key affected 
populations, such as people who use drugs and impris-
oned individuals at risk of non- adherence.11 12 Quanti-
tative and biomedical studies promote understanding 
about the prevalence and risk profiles of non- adherence 
among key affected groups,13 14 and can increase knowl-
edge on drug resistance profiles to antiretroviral therapy 
in different settings.8 Yet, there is a need for qualitative 
studies for identifying how and why engagement with 
and adherence to treatment decline, in addition to eluci-
dating the pathways that lead from the sociocultural, 
political and economic context to individual reasonings 
and reactions that determine behaviour.
Studies from other regions provide evidence within the 
socioecological framework of multiple influences on life-
long antiretroviral use.15–20 First, at a political level, health 
policies, incriminating laws and public health priorities 
influence HIV risk behaviours.21 Second, at a sociostruc-
tural level, poverty,22 HIV stigma,23 24 violence victimisa-
tion25 and cultural norms such as masculine stoicism26 can 
act as barriers to consistent antiretroviral therapy. Third, 
at an institutional level, appropriate services, quality of 
care, competent staff, supportive health workers and 
sufficient resources contribute to engagement in care 
and adherence to treatment.27 28 Fourth, at an interper-
sonal level, social support,29 relationship intimacy and 
personal satisfaction can impact adherence behaviour.30 
Fifth, the aforementioned contextual levels, directly and 
indirectly, shape the situations in which individuals cope, 
experience emotions, use drugs and engage with lifelong 
adherence.31–34 Moreover, factors within a socioecolog-
ical framework must be considered within the temporal 
junctures in which they meet; changes in political climate 
and policy directions could be a key contributor in 
shaping the coalescence of the influencing factors within 
individual lives.
This study was conducted using a social constructivist 
approach, augmented with a realist- informed analysis, 
to thematically investigate the pathways from the socio-
ecological context to individual cognitive and affective 
mechanisms that impede treatment for people living 
with HIV in Tehran, Iran. The research question for 
this study was how individuals react to their context in 
ways that shape their adherence behaviours. The qual-
itative nature of the study allowed consideration of 
the impact of the time period in which the study took 
place, including, for example, the increasing economic 
sanctions and inflation that exacerbated financial and 
psychological hardships. Augmenting the constructivist 
paradigm with a realist informed analysis enhanced the 
transferability of context- specific findings. Iran has 24% 
of HIV cases within the MENA region,2 and provides 
universal access to antiretroviral therapy, constituting 
a useful case study for exploring the socioecological 
pathways that shape engagement with antiretroviral 
therapy.
HIV epidemic in Iran
The HIV epidemic in Iran was initially driven through 
shared needles, but is now primarily driven through 
sexual transmission.35 It is estimated that 54 thousand 
people are living with HIV in Iran, a country with a total 
population of 85 million. By 2020, 42% of those living 
with HIV knew their status, of which 68% were receiving 
treatment. Only 81% of antiretroviral recipients achieved 
viral suppression in 2018, the only year in which this 
target was reported.2 Iran provides universal and free 
access to treatment through a decentralised model of 
health delivery across 31 provinces via university hospi-
tals, operating under the joint Ministry of Health and 
Medical Education, providing uniform services for HIV, 
including voluntary counselling and testing (VCT) 
centres and positive clubs for psychosocial support.
Failure to meet the 90- 90- 90 targets by 2020 and the 
loss of people along the care cascade, despite free provi-
sion of test- and- treat, signify socioecological barriers to 
diagnosis and care. Fear of prosecution and stigmatisa-
tion deter many from seeking HIV testing and treatment, 
despite immunity offered by patient confidentiality. 
Men who have sex with men are prosecuted only when 
there is a petition from a victim of sexual offence, and 
independent investigation of homosexual sex by police 
or prosecutors is subject to punishment by law. Never-
theless, perceived threat of prosecution and sentencing 
continues to deter many from reaching services. For addi-
tional information, see online supplemental appendix 1.
METHODS
Design and setting
Qualitative methods are useful for situating behaviour 
within the wider social context and generating roadmaps 
for intervention design.36–39 This social constructivist qual-
itative study was augmented by realist- informed analytical 
thinking for a deeper understanding of how behaviours 
are produced via context- specific cognitive and affective 
mechanisms that cannot be measured quantitatively.40 
Merging two research paradigms: social constructivism 
with realism, allowed the identification of cognitive and 
affective mechanisms as reactions to socioecological trig-
gers that may be socially constructed, but remain rooted 
in a shared reality, with transferable lessons to similar 
contexts.41 42 Rather than seeking to generate standard 
characterisations of all members of a statistically repre-
sentative sample, a social constructivist approach was 
used to answer the research question through an in- depth 
exploration of the diverse ways that antiretroviral users 
in this setting were responding to the socioecological 
context of living with HIV in Iran. A realist- informed 
thematic analysis was then applied to produce identifi-
able mechanisms that appear to shape HIV treatment 
adherence and engagement within Iranian socioecolog-
ical context. Thus, we were able to study how the under-
standings and actions of people living with HIV shape 
their engagement with and adherence to treatment, by 
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exploring their collectively constructed representational 
realities, and their reactions to it, instead of surveying a 
list of individual and societal characteristics as decontex-
tualised properties of a closed social system. The iden-
tified mechanisms and context- specific findings of this 
study will inform a future mixed- methods trial and realist 
evaluation of an intervention to be empirically tested 
within this population.
The study is part of an ongoing research project to 
understand and improve antiretroviral use of Iranians 
living with HIV, conducted at the infectious diseases 
unit of the Imam Khomeini Hospital Complex (IKHC), 
which is the teaching hospital of Tehran University of 
Medical Sciences and based in the sociodemographi-
cally diverse city centre of Tehran. IKHC houses Tehran’s 
central VCT centre, where participants of this study were 
recruited from over 4000 patients. Additional psycho-
social support is offered on- site at the peer- run positive 
club, a supportive location in which the study interviews 
took place. IKHC also houses the Iranian Research 
Centre for HIV/AIDS (IRCHA), the main collaborating 
research partner of this project, with a team of eight full- 
time researchers and research assistants, from which the 
staff for this project were recruited. Recruitment of study 
participants took place from August 2018 to January 
2019. All staff members conducting the recruitment and 
informed consent process were trained in the ethical 
treatment of human participants and were familiar with 
informed consent guidelines. Recruitment was indirect 
by asking healthcare providers to provide a brief intro-
duction to the study to patients during individual clinic 
visits. Patients who showed interest were then invited to 
visit IRCHA to provide written and informed consent, 
with the agreement that their identities would not be 
revealed. A meal was provided to show appreciation of 
the participant’s contribution to the study, on the day of 
the interview.
The qualitative study draws on the perspectives of both 
recently diagnosed and more experienced active antiret-
roviral users, and their healthcare providers. The research 
method involved interviews and focus group discussions 
(FGDs), both of which allow researchers to explore areas 
of interest, although with important differences in terms 
of approach. For instance, individual interviews allow an 
in- depth exploration of personal and sensitive topics, 
while FGDs involve group interactions with the possibility 
to assess consensus and dissent within a trusted environ-
ment among peers.43 The FGDs were conducted sepa-
rately for men and women to explore any differences 
between genders in their reactions to contextual triggers 
and the impact on antiretroviral therapy engagement. 
FGDs and interviews were recorded with the consent of 
participants, who chose their own nicknames to be used 
during the recording.Following transcription,the audio 
recorded files of participants’ voices were deleted and 
no information with personal identifiers were stored or 
accessible.
Sampling and analysis
Purposive sampling44 was used to recruit participants with 
a range of experience in terms of adherence to antiret-
roviral therapy, based on information in clinic records of 
people living with HIV receiving antiretroviral therapy, 
using the following criteria: (1) antiretroviral recipients 
diagnosed within the past year, (2) antiretroviral recipi-
ents diagnosed more than 1 year ago; (3) antiretroviral 
recipients who experienced disruptions in care and 
adherence and (4) antiretroviral recipients who had to 
change more than one treatment regimen due to drug 
resistance. For each of these criteria, men and women 
were sampled separately from clinical records. Partic-
ipants were phone- called by research staff, who were 
trained in informed consent process and introduced 
to the research project. An overview of information 
included in the consent forms was provided with regard 
to the study purpose and design and details regarding 
the length, location and general discussion points for 
the qualitative interviews. If interested, three dates were 
provided to choose for participation. A reminder phone- 
call was made 1 day prior to the scheduled date. On the 
day of the interview, participants were given informed 
consent sheets to read carefully before signing.
Twelve individual interviews and 8 FGDs with a total of 
27 female and 31 male patients were conducted. In addi-
tion, five individual interviews, with HIV care providers 
(two physicians, one counsellor, two peer supporters 
who were living with HIV) and one FGD, with a total of 
eight additional care providers (six physicians, one coun-
sellor, one nurse), were conducted. Focus groups had 
an average of six participants, with the aim of creating 
a smaller and more intimate environment for conversa-
tions. Individual interviews averaged 40 min and focus 
groups averaged 1.5 hours. Table 1 presents a summary 
of the characteristics of these participants.
Semistructured topic guides focused on what the 
socioecological barriers and facilitators to antiretro-
viral therapy adherence are—and how and why they 
impact antiretroviral adherence and use (Topic guides 
also covered potential approaches for intervention and 
current clinic support mechanisms; however, these are 
not discussed in detail in this paper.). Interviews were 
conducted by the lead researcher (VA), a native Persian- 
speaker and audiorecorded with permission from the 
participants. These recordings were subsequently tran-
scribed in Persian by VA and imported into MAXQDA, a 
qualitative analysis software package, for organising and 
coding the text segments with descriptive headings. Two 
researchers (VA and LT) coded the data independently 
in Persian. The emerging codes were reviewed in inter-
vals, after coding twenty per cent of the transcripts, by 
discussing differences in coding to reach an agreement. 
Differences focused largely on different meanings being 
attributed to specific words rather than disagreements 
about the emerging themes, thereby requiring alignment 
of language more than the need to resolve disagreements 
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about what the data meant. The agreed on themes were 
then translated into English.
Thematic network analysis was employed to summarise 
the main themes within web- like networks that illus-
trated pathways from the specific socioecological context 
of living with HIV in Iran to individual cognitive and 
affective mechanisms that impact treatment uptake and 
adherence. Following the prescribed steps for thematic 
network analysis,45 the transcribed texts were first coded 
with a basic code, informed by the socioecological 
framework of multilevel factors shaping antiretroviral 
therapy success; the basic codes were then clustered into 
higher order basic themes, identifying how the socioeco-
logical context produced specific cognitive and affec-
tive mechanisms of treatment uptake and adherence; 
the basic themes were then grouped by the identified 
contextual triggers into organising themes, which were 
then grouped by the cognitive and affective mecha-
nisms into global themes. The outcome of this thematic 
network analysis is presented in figure 1, highlighting 
Figure 1 Pathways from socioecological contextual triggers (organising themes) to cognitive and affective mechanisms 
(global themes) that disrupt antiretroviral therapy (ART).
Table 1 Participant characteristics
Study characteristics Antiretroviral recipients Healthcare providers Peer supporters Total
Research participation type
  Individual interview, no. 12 3 2 17
  Women, no. 4
  Men, no. 8
  Focus group, total no. (no. of groups) 58 (8) 8 (1) 0 58
  Women, no. (no. of groups) 27 (4)
  Men, no. (no. of groups) 31 (4)
Total participants, no. 70 11 2 75
  Mean age, years 38 58 41
  Women, no. (%) 31 (44)
  Men, no. (%) 39 (55)
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the pathways that produce context- specific cognitive and 
affective mechanisms, via the main themes that address 
the research question and build the structure for the 
presentation of our findings.
RESULTS
The findings of our study identify cognitive and affec-
tive mechanisms that hinder adherence to antiretroviral 
therapy situated within the socioecological context of 
living with HIV in Iran, as opposed to decontextualised 
individual reasonings and reactions. The mechanisms 
specific to, and triggered within, the socioecological 
context of living with HIV in Iran appear to be: denial 
in response to societal negative perceptions of HIV; fear 
in response to societal lack of awareness regarding HIV 
and misinformation, and despair in response to HIV- 
related stigma and enacted discrimination, economic 
insecurity and lack of social support. Thematic pathways 
from socioecological contextual triggers to cognitive and 
affective mechanisms that disrupt antiretroviral therapy 
are depicted diagrammatically in figure 1 and summa-
rised in table 2. The results section is presented in terms 
of the cognitive and affective mechanisms, within which 
are located further subsections based on socioecological 
contextual triggers. The mechanisms are presented in 
the order that they appear to be experienced as navi-
gating through HIV care cascade after diagnosis: first 
experiencing denial and fear, followed by despair. For 
each cognitive and affective mechanism, a summary of 
gender differences is provided, as assessed by the extent 
to which each theme was emphasised among men versus 
women.
Denial as a cognitive mechanism
Denial was identified as a cognitive mechanism under-
pinning the rejection of the HIV diagnosis and need for 
treatment, motivated by the need to escape the negative 
societal perceptions regarding HIV. This mechanism was 
triggered in the initial stages of the HIV care cascade, 
exposing HIV diagnosed patients to an increased risk of 
harmful drug use due to the need to escape from the 
new reality of living with HIV. Denial appears to be the 
primary mechanism producing a lengthy gap between 
diagnosis and enrolment in care. As a coping mecha-
nism, male interviewees commonly reported referring to 
denial and were more likely to use words such as ‘not 
being in acceptance’ and ‘being in denial’.
Negative societal perceptions regarding HIV
A number of interviewees described the ways in which 
negative perceptions regarding HIV in the wider society 
triggered a state of denial following diagnosis. To avoid 
any association with the condition, some participants 
chose to not initiate or discontinue treatment.
The perception that people give is very negative. It’s like it 
feels better to stay in denial even if you have it, to run away, 
but you don’t realise that you are hurting yourself more. 
(Male patient—focus group 5)
The name of this disease is more negative than anything 
in our society. Because of it they blame you and embarrass 
you. It’s not like cancer or anything else that you are the 
victim. (Male patient—interview 1)
Denial appeared to have hindered the decision to 
enrol in care in the first place, delaying the initiation of 
care until the point that CD4 levels were too low.
It took me exactly six years to come out of the denial stage. 
When I started treatment my CD4 was 8, I couldn’t walk, I 
couldn’t breathe. I couldn’t move. It’s like you are in that 
denial stage in the beginning. Until you accept HIV, make 
other friends [who live with HIV], get treatment and get 
help. (Male patient—interview 7)
Using drugs, particularly trying new drugs and new 
routes of administration, were also described as a form 
Table 2 Thematic network analysis of basic, organising and global themes
Global 
themes
Mechanisms
Organising themes
Contextual triggers
Basic themes
How context triggers mechanisms
Denial
cognitive
Negative perceptions Denial can be a coping mechanism to adjust to negative social perception of HIV.
Staying in denial can delay treatment and encourage harmful drug use.
Fear
affective
Lack of awareness Fear appears to be caused by lack of societal awareness of HIV and ART.
Misinformation Fear can be triggered as a result of misinformation.
Despair
affective
Perceived stigma Despair appears to be felt in response to perceived stigma against HIV status.
Newly diagnosed patients can experience stronger despair, which can cause 
depression.
Enacted discrimination Despair can be an emotional response to acts of discrimination by the society.
Discrimination by families and medical society can produce stronger despair.
Economic insecurity Despair can be an emotional response to economic insecurity.
Social support Despair appears to be felt when social support is lacking.
Supportive family and services can moderate feelings of despair.
ART, antiretroviral therapy.
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of escape from the new reality of living with HIV, with 
significant long- term consequences for those who used 
more lethal types of drugs.
I had a friend who passed away. He went towards these 
new substances [methamphetamines] that are complete-
ly different from the traditional substances [opiates]. In 
one month, they [methamphetamines] do the harm of 
10 years of substance use. Before he exercised, he was in 
shape. But after his HIV diagnosis he just drowned him-
self in these substances [methamphetamine] and was soon 
gone. (Male patient—focus group 1)
Fear as an affective mechanism
Fear was identified as an affective mechanism in response 
to HIV treatment being perceived as daunting, and 
thereby avoided. As incorrect information is propagated 
through society, fear can spread easily among people 
living with HIV. More women, than men, cited fear as a 
mechanism of avoiding treatment.
Lack of societal awareness regarding HIV
Participants talked about a general lack of awareness of 
HIV in Iranian society due in part to the fact that HIV- 
related topics are not widely discussed in the society, 
thereby many people have never heard about HIV, still 
think of it as a death sentence, and lack knowledge with 
regards to the availability of treatment. The interviews 
indicated that existing knowledge about HIV tended to 
be superficial, and that the condition itself was perceived 
to be stigmatising, leading to fear and a disinclination to 
seek treatment.
When I found out I have HIV I was shocked and afraid. I 
never even thought that in Iran anyone has HIV. I thought 
it only happens in other countries or to people who act 
transgressively. (Female patient—interview 4)
People are not even aware that now you can get treated 
and view [HIV] with fear. They don’t see a difference 
between HIV and AIDS. You will be labelled [pejoratively] 
as ‘AIDS- y’. This makes it scary to show up appointments. 
You just prefer to stay away. (Male patient—interview 10)
Misinformation
Participants indicated that a range of issues related to 
medications could trigger fear and mistrust of antiretro-
viral therapy. Some described fear of long- term therapy 
affecting their ability to adapt to daily medication sched-
ules.
I really don’t like medicines in general, so the thought that 
I have to take 60 pills every month was scary to me and it 
took me a long time to get used to this. (Female patient—
focus group 8)
I was really scared of these drugs [antiretrovirals]. I wasn’t 
sure how sure I could be about how safe and useful they 
are. (Female—interview 5)
A peer counsellor recounted misinformation, false 
beliefs, and conspiracy theories, being disseminated 
among patients through waiting rooms and online 
chatrooms.
Some patients don’t even believe in chemical medications. 
From the beginning, they go towards traditional medicine 
and say why should we take these drugs. They think they’ve 
been ‘turned into lab mice’. This is their perspective. They 
also find scary information online and share with others in 
waiting rooms and chat groups. (Female peer counsellor—
interview 1).
Concerns regarding treatment side effects appeared 
often to be shared leading to misinformation and trig-
gering fear of treatment initiation in new patients.
When they speak about the side- effects of medications, 
they create such fear that new patients sometimes delay 
beginning treatment, or they won’t start until they have 
become very ill. Sometimes patients start to imagine they 
are experiencing side effects, for example saying that ‘the 
drugs do not descend from their throat into their stom-
ach’. (Female peer counsellor—interview 1).
Despair as an affective mechanism
Despair was identified as an affective mechanism that led 
to treatment adherence being perceived as meaningless 
and, subsequently, deprioritised. The societal context of 
HIV- related stigma, enacted discrimination against HIV 
status and economic insecurity appeared to be the key 
contextual triggers for despair, sometimes causing depres-
sion. However, social support appeared to mitigate some 
of the despair that resulted from contextual adversities, 
while lack of support engendered more despair. Despair, 
as an underpinning motivator of e with treatment was 
commonly referred to by female interviewees, especially 
in the context of family problems. Some women inten-
tionally stopped adherence when they felt uncared for 
and depressed. Female respondents were more likely to 
use words such as ‘wanting to give up on life’ and ‘prefer-
ring to die early’.
HIV-related perceived stigma
Participants described how from the onset of HIV diag-
nosis, the experience of HIV- related stigma and the 
feeling of being rejected by society, created a sense of 
despair and in some cases depression, weakening the 
motivation to continue adherence with treatment.
This adherence to treatment requires motivation, hope. 
But a big problem that we have is problems which stem 
from the stigma [of HIV]. Sometimes the pressures from 
stigma and the attitude of the society are so strong that 
you just lose hope and want to end the whole process of 
treatment. And it has happened to many of us. (Female 
patient—interview 2)
Indeed, the interview data suggest that stigma widely 
disrupts the social conditions in which people living with 
HIV interact with society and form relationships.
Stigma in this society is what makes everything in life more 
difficult for us, from medical treatment to the possibility of 
marriage. (Male patient—focus group 5)
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The first year following diagnosis appeared to be the 
most sensitive period, in which the shock of being diag-
nosed with HIV combined with the experience of stigma 
contributed to the erosion of hope. Some participants 
appeared to have internalised the stigma in the early 
days, leading to isolation and depression, further dimin-
ishing adherence.
Unfortunately, in our society we have to live with this stig-
ma, and in the beginning, you also believe this stigma your-
self, so you are more depressed and live a hopeless life. 
(Female patient—focus group 4)
The early days were terrible. You know about stigma, but 
you do not expect to feel so much emotional pain because 
of it. You just retreat within yourself and this impacts 
your ability to function, let alone taking your treatment 
seriously. (Female patient—focus group 2)
Enacted discrimination against HIV status
Acts of discrimination against HIV were described to be 
present in all segments of the society and identified as a 
key trigger for despair.
When people discriminate against us [patients living with 
HIV] it’s like the higher the education levels, the lower the 
‘sho’oor’ (social intelligence), so you really lose hope. (Fe-
male—focus group 4)
My only problem is feeling depressed because people in 
the society do not accept us, they don’t accept HIV, so I get 
hurt. (Female—focus group 2)
Many participants described being disowned by their 
families and whole communities when they discovered 
that they were living with HIV. Rejection by families 
appears to have forced some participants into homeless-
ness, migration and situations of severe adversity that 
hinder treatment adherence. This experience appeared 
to be more common among ethnic minorities and less 
common in Tehran.
When I found out I didn’t tell anyone, but my brother 
found out, collected all my clothes, and threw me out of 
the house. A few weeks ago, I went for my uncle’s funer-
al. The whole family asked my brother why he made me 
homeless. He easily said to my parents that I have HIV, and 
they all disowned me. (Male—Interview 3)
I was thrown out of the house and had to leave my commu-
nity when they found out I am HIV positive. I ran away and 
came to Tehran and for 5 years I was sleeping in the streets, 
under the bridges of this city. These things are more com-
mon among us [ethnic minorities]. (Male Patient—Focus 
group 1)
Interviewees also described acts of discrimination by 
medical practitioners, outside the circle of HIV experts. 
Nurses, dentists and general practitioners were described 
as having a discriminatory attitude and as refusing 
medical and dental care to people living with HIV. This 
experience was described as intensifying despair, depres-
sion and withdrawal from care.
When I go to the doctor unrelated to HIV, and they realize 
that I have HIV, their attitude changes. I have a glass of 
water and the doctor says to put the glass in the bin out-
side his office, or to not use the toilette in his office. Of 
course, this intensifies my depression. (Female patient—
focus group 8)
In many cases the refusal to provide treatment to a 
patient occurred within the context of a breach of confi-
dentiality within the hospital wards or clinics where they 
were receiving care that was unrelated to HIV.
I found out I have HIV when I was getting chemo-
therapy and was in my third session. The doctor told me 
to get tested for HIV and when I went back and told them 
I am positive they treated me with unbelievable avoid-
ance. The nurses didn’t even want to change my IV. They 
talked behind my back and told everyone in the ward 
that I have HIV. I just didn’t go for my fourth session of 
chemotherapy. (Male patient—focus group 7)
An absence of dental care was described as impacting 
antiretroviral adherence in older patients who had not 
received necessary dental care and for whom food intake 
was compromised as a result, leading to nutritional prob-
lems that affected antiretroviral adherence.
So many dentists refused care to me, so I lose hope in them 
[dentists] and stop going for visits. For medication adher-
ence, nutrition is most important, especially for older peo-
ple like me. I now need to remove two of my teeth, but I 
can’t go. (Female patient—focus group 6)
Economic insecurity
Financial insecurities are not a direct barrier to accessing 
treatment, given the provision of free and universal 
antiretroviral therapy in Iran. However, economic inse-
curity, caused by sanctions and inflation, appeared to 
have had a strong impact on the ability of people living 
with HIV to manage more generally, leading to feelings 
of despair, and in some cases suicidal thoughts. One 
participant described not wanting to continue with life as 
a result of constant price increases.
Constant price increases bring you down [emotionally], so 
then you have no motivation to look after yourself. Adher-
ence to treatment in reality is looking after yourself. (Fe-
male patient—focus group 8)
This year I just can’t take the prices anymore. I’ve been 
thinking about giving up on this life. I just can’t stop cry-
ing. It’s getting harder every day and I can’t continue this 
life anymore. (Female patient—focus group 8)
Sometimes the cost of living is so high that you feel like 
you are breaking under this life, everything becomes a 
challenge from waking up in the morning to taking your 
medications. (Male patient—Interview 6)
Participants noted that they would have stopped 
antiretroviral therapy if it were not free, but nutritional 
supplements prescribed by physicians were described as 
becoming increasingly unaffordable.
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If they didn’t give us the medicines for free I would defi-
nitely not take [antiretroviral therapy]. Because for ex-
ample right now doctor told me to take vitamin E and to 
take iron because I have ‘Kist’ (Cystitis). I try to buy it but 
sometimes when I don’t have enough money I don’t buy. 
Because right now all the prices have gone up. (Female 
patient interview 3)
One doctor described that economic hardship drives 
people to profit in the black- market by selling their medi-
cation on the streets as pre- exposure prophylaxis.
We don’t offer universal PrEP, so some patients who are in 
need go and sell their own medications as PrEP to others 
in the black market, so they end up not adhering properly. 
(Doctor—focus group with healthcare providers)
Social support
The data also suggest that the existence or lack of social 
support can moderate despair. Participants described 
how the lack of family and social support made them feel 
‘uncared for’ and was another trigger for despair and 
stopping treatment.
I don’t have any support. In my family there is no one to 
help and support me to take my medicine. I have health 
problems and was in the emergency room, but it wasn’t 
even important to them. I considered stopping the medi-
cines all together. (Female patient—interview 11)
Feeling beset by family problems unrelated to HIV, led 
to one participant stopping treatment because she could 
no longer see the value in life.
For me what causes me to not take my medicine is prob-
lems in life. I have problems with my husband, I stop taking 
my medicine. I face problems with my family, my father 
and my mother, I can’t take it at points, so I really lose hope 
in life, and I leave my medicine aside. It’s like everything 
loses its importance for me. Living life loses its value. (Fe-
male patient—focus group 2)
The presence of social support was also perceived to be 
helpful in enabling some participants to cope better with 
adherence.
I am very lucky because my family is very supportive. They 
help me a lot and even called our relatives who live in 
America to get information for me from mayo clinic and 
make sure I am getting the right care and that has been 
very reassuring for me. (Female patient—focus group 2)
The importance of having access to empowering 
classes, peer support clubs, harm reduction opportuni-
ties for quitting drugs and online support groups was 
highlighted by many participants. Interviewees who had 
taken advantage of such opportunities referred to devel-
oping a sense of self- love and an awareness of the need 
to take care of themselves, which they felt had protected 
against self- harm and non- adherence:
They teach us the art of life here. We used to even play mu-
sic here, and these helped me come out of my depression. 
With time and counselling I realised that I am doing this 
[being on treatment] for myself. I have to love myself first, 
otherwise who will. (Male patient—interview 9)
I joined the Positive Club [Peer Support Club], they taught 
us a lot here. I started methadone, helped me get clean 
and come out of darkness and instead take care of myself. 
The classes taught us life- skills. I ended up even finding a 
job and going back into the society. (Male patient—focus 
group 5)
We help each other online, for example if a person runs 
out of medicine, we send it to them until they can go and 
get their pills. Our telegram groups have been helpful for 
us to look after each other. (Male patient—focus group 1)
Participants especially enjoyed the interaction with 
‘positives’ (Persian term for living with HIV), and caring 
healthcare staff.
When I discovered the positive- club, I realised that I am 
not alone, and talking to other positives really gave me mo-
tivation to take care of myself. (Male patient—interview 1)
The staff here are really exceptional. Every one of them are 
very dear to me. Just knowing that they care gives us hope. 
It also helps that some of them are positives themselves and 
we share this pain together. (Female patient—focus group 
2)
DISCUSSION
In this study, we aimed to identify pathways through 
which the socioecological context of living with HIV in 
Tehran, Iran, leads to cognitive and affective mecha-
nisms that shape engagement with antiretroviral therapy. 
To the best of our knowledge, this paper presents the 
first in- depth exploration of engagement with and treat-
ment adherence in a MENA country. Previous studies 
from MENA, most of which are from Iran, are largely 
composed of quantitative surveys, producing lists of risk 
and protective factors for treatment adherence.7–14 Our 
findings suggest that the three key affective and cogni-
tive mechanisms of denial, fear and despair undermine 
successful and lifelong treatment. We detail the ways in 
which denial and fear are triggered through a context of 
negative societal perceptions, lack of awareness regarding 
HIV and widespread misinformation. While despair is 
described as occurring in response to experiencing HIV- 
related stigma, acts of discrimination and living through 
economic insecurity, it is perceived to be moderated by 
social support. Importantly, we observed a temporal effect 
in terms of Iran’s rapidly changing economic climate on 
the experience of despair and its influence on lifelong 
treatment.
Denial appears to be a cognitive mechanism that drives 
many away from treatment in an attempt to escape the 
negative societal perceptions regarding HIV, especially 
in the early stages following diagnosis. Recognised as 
the first of five stages of grief,46 denial was similarly iden-
tified to be a coping mechanism following HIV diag-
nosis. However, participants in this study retrospectively 
reported unusually lengthy periods of being in denial 
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and delaying treatment initiation, sometimes until they 
experienced AIDS- related illnesses and low CD4 counts, 
despite the availability of treatment at the time of diag-
nosis. While in denial, some participants began to exper-
iment with new classes of drugs (eg, methamphetamine) 
or new routes of drug administration (eg, increased 
injection), ultimately risking losing their life to harmful 
drug use.
More men than women described reacting through 
denial and avoidance, while more women described feel-
ings of despair and depression. The former appears to act 
more as a barrier to enrolment and the latter to adher-
ence. This potential difference between genders could 
be rooted in previously documented hegemonic notions 
of masculinity,47 48 whereby men view HIV as a threat to 
their manhood and dignity and are wary of any associ-
ation with HIV.26 49 In the process of denying the diag-
nosis, they refuse treatment and may also prevent women 
and other members of their household from accessing 
treatment services.26 49 It was not within the scope of this 
study to explore how gender norms are defined within 
the Iranian context, or whether hegemonic notions 
of masculinity apply in the same way as findings from 
Zimbabwe in relation to HIV.26 49 We are highly cogni-
sant of not commenting on gender roles in stereotypical 
orientalising ways. Iranian society is undergoing highly 
rapid, dynamic and complex changes with regard to 
gender norms and roles. The past 40 years has expanded 
access to higher education, especially for women, who 
now make up more than half of university students, 
and more than sixty per cent of science and technology 
students. Female participation in the workforce is also 
rapidly increasing as influenced by an expanding service 
industry and by economic insecurities of single- income 
households. Future research can further explore if and 
how the changing gender norms impact the success 
of antiretroviral therapy in Iran and the larger MENA 
region.
Fear also appears to be an affective mechanism that can 
hinder treatment. Lifelong adherence has been more 
easily achieved in contexts where there is an acceptance 
of HIV status,26 50 allowing patients to fit medication 
schedules into their lives without the impact of fear and 
stigma.51 Our findings suggest that in contexts were HIV 
has a low prevalence and high stigma, such as the MENA 
region, lack of societal awareness regarding HIV and 
misinformation regarding treatment are key contributors 
to fear of antiretroviral therapy. While concerns about 
side effects and medical anxiety are valid and that they 
must be addressed, study participants reported having 
postponed treatment initiation due to the fear associated 
with attending appointments or resulting from intimi-
dating information they received regarding antiretroviral 
therapy. This finding corroborates previous evidence 
suggesting that in low HIV- prevalence settings, where the 
wider society still lacks awareness and knowledge about 
the HIV epidemic, not only does the struggle for recog-
nition still continue,5 but daily adherence and lifelong 
engagement with treatment are sought in the face of 
much more powerful experiences of societal negative 
perceptions and incorrect knowledge regarding HIV.52
Despair was reported to be a key affective state in which 
people living with HIV reduce or intentionally stop adher-
ence to treatment. Participants lose hope and the moti-
vation for adherence when HIV- related stigma, enacted 
discrimination against HIV status and economic insecu-
rity seem overwhelming. The experience of HIV- related 
stigma and discrimination has been associated with 
reducing treatment success in previous studies.23 24 Here, 
we have identified despair as a key construct within the 
pathway from the social context of stigma and discrimi-
nation to treatment engagement and lifelong adherence. 
This finding adds to a more recent body of evidence, 
highlighting despair as a new driver of morbidity and 
mortality.53
Importantly, despair appears to be manifested when 
economic stagnation dominates the lives of individ-
uals.54 55 The phenomenon of ‘deaths of despair’ was 
first identified in the USA, suggesting that social and 
economic immobility produce morbidity and mortality 
through despair, demanding public health attention.54 55 
Following the 2018 reimposition of sanctions on Iran, 
the Iranian Rial lost half of its value during this study’s 
data collection period,56 with continued devaluation and 
steep inflation rates to the present time.57 Many partic-
ipants expressed loss of hope and suicidal thoughts in 
response to the continuously increasing economic pres-
sures they felt and their decreasing ability to manage 
financially. This finding suggests new causes of morbidity 
and mortality linked to despair that is driven in a climate 
of economic insecurity, sanctions and inflation. It 
appears that for Iranians living with HIV, despair caused 
by economic insecurity can undermine motivation for 
adherence, drive intentional disengagement with care 
and lead to suicidal thoughts. While global health studies 
often ignore the health impacts of different economic 
realities, the findings of the current study suggest the 
need for further investigation into despair- driven adverse 
health events within the context of such realities, partic-
ularly for vulnerable groups such as people living with 
HIV.
Moreover, this study sheds light on the importance of 
people’s behaviours and responses within the context of 
their lives as lived through time.58 For instance, in Iran, 
the drive to harmful drug use must be understood within 
a context in which people lose hope, or rather stay in 
denial, in the face of HIV- related stigma, discrimina-
tion and misinformation, sometimes resulting from low 
awareness at a societal level. The HIV epidemic is highly 
dynamic in terms of transmission routes, the populations 
affected and the resources available at any given social 
and economic time point.59 60 Drug use patterns in Iran 
have changed substantially over time,60 from an older 
generation that smoked opium to a younger generation 
that injects heroin, and a recent increase in methamphet-
amine use across all ages and socioeconomic groups.60 
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These transitions have been linked to drastic political 
and economic changes, from the aftermath of an 8- year 
war to over three decades of sanctions, inflation and 
un(der)employment,59 thereby revealing the impact of 
temporal junctures in which politics and economics can 
have a significant direct and indirect impact in terms of 
health outcomes.
Our findings also show that in the face of adversities 
linked to living with HIV, social support plays a key role in 
enhancing or reducing hope. Perceived lack of support, 
especially in terms of unsupportive family members, 
appears to fuel despair and disrupt adherence, with some 
participants reporting intentionally stopping adherence 
as a result of not feeling cared for. Moreover, compe-
tent healthcare providers and peers can have a positive 
impact in helping people living with HIV overcome diffi-
culties in making sense of their experiences and nego-
tiating support. Many antiretroviral users indicated the 
rewarding and positive relationships with healthcare staff 
and peer supporters that were viewed as enabling them to 
gain optimal benefits from the healthcare system. Access 
to caring support appears to dilute the experiences of 
stigma and discrimination from the wider society. Partici-
pants especially enjoyed the interaction with peers living 
with HIV, through which a feeling of ‘us’—the ‘positives’ 
in Persian—and the uninformed and hostile ‘others’ 
enables an empowering distinction. Online and offline 
support networks in which patients give and receive 
supportive information appear to be particularly valued.
At its onset, the HIV epidemic in Iran was producing 
more deaths by suicide than HIV- related causes.59 61 In 
response, community outreach programmes mobilised 
to provide culturally sensitive support and counselling 
to HIV- affected families who had disowned their kin who 
were diagnosed with HIV.62 63 This work was followed by the 
development of triangular clinics, which provided treat-
ment for drug use, HIV and other sexually transmitted 
diseases; a model that diffused stigma by avoiding direct 
reference to HIV/AIDS and resulting in a growing uptake 
of HIV testing.61 Other national strategies to support 
those living with and those at risk of HIV include peer 
support clubs, harm reduction programmes, methadone 
maintenance treatment, needle exchange programmes 
and free counselling for people who use drugs.63 These 
programmes have reduced the number of people living 
with HIV who turn to suicide and have improved harm 
reduction for people who use drugs.59 Yet, given that the 
HIV epidemic in Iran remains hidden from the general 
public and is absent from public debate, universal access 
to antiretroviral therapy is failing to achieve its promise 
in the absence of public recognition and support for 
people living with HIV. Therefore, more interventions 
that are culturally appropriate, contextually sensitive and 
tailored to the dynamically changing needs of individuals 
are necessary to improve the lived experience of Iranians 
living with HIV.58
The findings from this study have informed an inter-
vention for improving engagement with and adherence 
to antiretroviral therapy for people living with HIV in 
Iran. Rather than simply orienting the intervention to the 
outcome of improving adherence, the findings from this 
study have been used to develop a personalised mobile 
health intervention that is oriented to Iran’s particular 
socioecological context, tailored to individual cognitive and 
affective states, and attuned to the political and economic 
climate of the time.58 Previous evidence demonstrates that 
mobile health strategies are a low- resource option that can 
make people living with HIV feel cared for,64 offer tailored 
and temporally adaptive support and maintain patient 
privacy.65–67 Such digital strategies have the added benefit of 
augmenting existing infrastructure (eg, harm- reduction and 
peer support programmes) to enable patients in making 
optimal use of available services.68 69 While public aware-
ness campaigns are chiefly needed to change the attitude 
of Iranian society towards HIV, personalised mobile health 
strategies will help people living with HIV to benefit more 
widely from available care and mitigate the experiences of 
‘deadly stigma’.3
Strengths and limitations
This qualitative study provided participants with an oppor-
tunity to discuss their perceptions of Iran’s HIV context 
and define their responses to that context, thereby giving 
voice to a population living within the hidden context of 
the HIV epidemic in Iran. This enabled us to capture the 
nuances of experience in terms of living within HIV within 
this particular socioecological context and thereby to iden-
tify the cognitive and affective states that can shape antiretro-
viral use. Moreover, the coding and analysis was conducted 
in Persian by two independent researchers, who are native 
speakers of the language. This approach ensured that the 
essence of language, used by participants, was not lost within 
the analysis of the emerging themes.
Participation in this study was voluntary with recruit-
ment from an HIV/AIDS clinic, and the sample may 
have been biased toward more motivated patients, who 
were able to overcome and report retrospectively on 
multiple barriers to lifelong treatment, including (but 
not limited to) stigma, transportation costs and oppor-
tunity costs. However, in accordance with principles of 
social constructivist research,70 rather than seeking to 
generate characterisations of all members of a statistically 
representative sample, an in- depth exploration of a small 
sample was undertaken to identify the diverse ways that 
the lived experience of people living with HIV influences 
their reasoning and reactions in terms of their relation-
ship with antiretroviral therapy.
CONCLUSIONS
Our findings suggest that engagement with and adherence 
to antiretroviral therapy are disrupted when people living 
with HIV respond to Iran’s socioecological context through 
the cognitive and affective states of denial, fear and despair. 
Therefore, in addition to the availability of free antiretroviral 
therapy, more awareness about HIV is needed to prevent 
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the rejection of treatment caused by denial and fear, and to 
provide hope and motivation for lifelong engagement with 
antiretroviral therapy. We observe that the low prevalence of 
HIV in Iran has stymied societal awareness and knowledge 
regarding HIV and antiretroviral therapy. Moreover, we 
note that the profound experiences of despair, in response 
to harsh economic conditions, jeopardise hope and motiva-
tion for continued adherence. Our findings support recent 
calls for the study of global health not be decoupled from 
that of international power politics,71 and emphasises the 
importance of understanding the nuances of experience 
that impact health decisions within the social and structural 
context of HIV.36 38 72
Twitter Vira Ameli @viraameli
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